BR0209238A - Compostos úteis como intermediários - Google Patents

Compostos úteis como intermediários

Info

Publication number
BR0209238A
BR0209238A BR0209238-7A BR0209238A BR0209238A BR 0209238 A BR0209238 A BR 0209238A BR 0209238 A BR0209238 A BR 0209238A BR 0209238 A BR0209238 A BR 0209238A
Authority
BR
Brazil
Prior art keywords
intermediates
compounds useful
compounds
useful
cetp
Prior art date
Application number
BR0209238-7A
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0209238A publication Critical patent/BR0209238A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTOS úTEIS COMO INTERMEDIáRIOS". Esta invenção refere-se a compostos úteis como intermediários para inibidores da proteína de transferência do éster colesterílico (CETP) e métodos para a preparação destes.
BR0209238-7A 2001-04-30 2002-04-08 Compostos úteis como intermediários BR0209238A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30
PCT/IB2002/001217 WO2002088069A2 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatives

Publications (1)

Publication Number Publication Date
BR0209238A true BR0209238A (pt) 2004-06-15

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0209291-3A BR0209291A (pt) 2001-04-30 2002-04-08 Métodos para preparação de inibidores de cetp
BR0209238-7A BR0209238A (pt) 2001-04-30 2002-04-08 Compostos úteis como intermediários

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0209291-3A BR0209291A (pt) 2001-04-30 2002-04-08 Métodos para preparação de inibidores de cetp

Country Status (25)

Country Link
US (3) US6600045B2 (pt)
EP (2) EP1383734B1 (pt)
JP (2) JP3924251B2 (pt)
KR (2) KR100591998B1 (pt)
CN (3) CN1267411C (pt)
AR (3) AR035963A1 (pt)
AT (2) ATE321755T1 (pt)
AU (1) AU2002253448B2 (pt)
BR (2) BR0209291A (pt)
CA (2) CA2445623A1 (pt)
CZ (2) CZ20032898A3 (pt)
DE (2) DE60209004T2 (pt)
DK (2) DK1425270T3 (pt)
ES (2) ES2259080T3 (pt)
HK (1) HK1062294A1 (pt)
HU (2) HU225777B1 (pt)
IL (2) IL157546A0 (pt)
MX (2) MXPA03009936A (pt)
PL (2) PL366700A1 (pt)
PT (1) PT1425270E (pt)
RU (2) RU2259355C2 (pt)
TW (1) TWI250974B (pt)
WO (2) WO2002088085A2 (pt)
YU (2) YU84303A (pt)
ZA (2) ZA200306599B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
BR0315041A (pt) 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
EP1594843B1 (en) 2003-02-18 2013-05-22 Takasago International Corporation METHOD FOR PRODUCING AN OPTICALLY ACTIVE beta-amino acid derivative
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
BRPI0407954A (pt) * 2003-03-17 2006-03-07 Kaneka Corp processo para a produção de derivado de amida de ácido (r)-3-[4-(trifluorometil) fenilamino]-pentanóico
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
KR20060085675A (ko) * 2003-10-08 2006-07-27 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
WO2005046662A2 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
MXPA06011540A (es) * 2004-04-07 2007-01-26 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
ZA200707498B (en) 2005-02-24 2008-11-26 Millennium Pharm Inc PGD2 receptor antagonists for the treatment of inflammatory diseases
KR20080016933A (ko) * 2005-06-20 2008-02-22 아스트라제네카 아베 (알콕시카보닐아미노)알킬 설포네이트의 제조 방법
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
BR112013026280A2 (pt) 2011-04-12 2024-04-30 Chong Kun Dang Pharmaceutical Corp Derivados de cicloalquenil arila para inibidor da cetp
AU2012282109B2 (en) 2011-07-08 2016-06-23 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
PT2943474T (pt) 2013-01-31 2017-08-08 Chong Kun Dang Pharmaceutical Corp Compostos biarilo ou biarilo heterocíclico como inibidores de cetp
US9458180B2 (en) * 2013-11-11 2016-10-04 Lonza Ltd. Method for preparation of cyano compounds of the 13th group with a lewis acid
DK3180314T3 (da) * 2014-08-12 2022-08-29 Newamsterdam Pharma B V Fremgangsmåde til fremstilling af syntetiske mellemprodukter til fremstilling af tetrahydroquinolin-derivater
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360634T1 (de) 1998-07-10 2007-05-15 Massachusetts Inst Technology Ligande für metalle und verbesserte metall- katalysierte verfahren, die darauf basieren
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.

Also Published As

Publication number Publication date
EP1383734B1 (en) 2006-02-01
DE60209004T2 (de) 2006-09-28
KR100591998B1 (ko) 2006-06-22
US6689897B2 (en) 2004-02-10
CA2445693A1 (en) 2002-11-07
ES2256461T3 (es) 2006-07-16
US6706881B2 (en) 2004-03-16
HK1062294A1 (en) 2004-10-29
AR036331A1 (es) 2004-09-01
CN1505609A (zh) 2004-06-16
PL366700A1 (en) 2005-02-07
WO2002088085A3 (en) 2004-03-25
ATE321755T1 (de) 2006-04-15
HU225777B1 (en) 2007-08-28
YU84303A (sh) 2006-05-25
JP3924250B2 (ja) 2007-06-06
KR20040015200A (ko) 2004-02-18
CA2445623A1 (en) 2002-11-07
MXPA03009935A (es) 2004-01-29
CN1529696A (zh) 2004-09-15
AU2002253448B2 (en) 2007-07-05
HUP0304039A3 (en) 2005-10-28
CZ20032898A3 (cs) 2004-07-14
RU2265010C2 (ru) 2005-11-27
IL157546A0 (en) 2004-03-28
US20020177716A1 (en) 2002-11-28
PL366584A1 (en) 2005-02-07
DE60209004D1 (de) 2006-04-13
HUP0304041A2 (hu) 2004-04-28
US20030216576A1 (en) 2003-11-20
WO2002088085A2 (en) 2002-11-07
ZA200306599B (en) 2004-10-22
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
BR0209291A (pt) 2004-07-13
AR035963A1 (es) 2004-07-28
JP2004531541A (ja) 2004-10-14
EP1425270A2 (en) 2004-06-09
JP3924251B2 (ja) 2007-06-06
RU2003131871A (ru) 2005-04-10
MXPA03009936A (es) 2004-01-29
CN1267411C (zh) 2006-08-02
DE60210265T2 (de) 2006-10-12
EP1383734A2 (en) 2004-01-28
DK1425270T3 (da) 2006-07-03
WO2002088069A3 (en) 2003-02-20
CN1297541C (zh) 2007-01-31
DK1383734T3 (da) 2006-05-15
PT1425270E (pt) 2006-07-31
CN1680292A (zh) 2005-10-12
TWI250974B (en) 2006-03-11
AR044706A2 (es) 2005-09-21
ATE316957T1 (de) 2006-02-15
CN100357265C (zh) 2007-12-26
CZ20032900A3 (cs) 2004-06-16
YU84403A (sh) 2006-08-17
HUP0304039A2 (hu) 2004-03-29
US6600045B2 (en) 2003-07-29
IL157544A0 (en) 2004-03-28
WO2002088069A9 (en) 2003-12-04
US20030073843A1 (en) 2003-04-17
EP1425270B1 (en) 2006-03-29
WO2002088069A2 (en) 2002-11-07
HUP0304041A3 (en) 2005-08-29
DE60210265D1 (de) 2006-05-18
ES2259080T3 (es) 2006-09-16
ZA200306600B (en) 2004-08-25
JP2004527556A (ja) 2004-09-09
RU2003131870A (ru) 2005-01-27
KR100639745B1 (ko) 2006-10-30

Similar Documents

Publication Publication Date Title
BR0209238A (pt) Compostos úteis como intermediários
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
SV2003001103A (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester pc10894
BR0211502A (pt) Derivados de ácido acético de indano e seu uso como agentes farmacêuticos, intermediários, e método de preparação
AU2002359522A8 (en) Compositions and methods of selective nucleic acid isolation
HN2001000018A (es) Carboxamidas de pirimidina utiles como inhibidores de isozimas pde4.
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
SV2003000741A (es) Compuesto lactamico x-13170
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
AU2002364435A1 (en) Novel inhibitor compounds specific of secreted non-pancreatic human aless thansbgreater than2less than/sbgreater than phospholipase of group ii
BRPI0412834A (pt) derivados de nicotinamida usados como inibidores da pde4
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
EP1435932A4 (en) INHIBITORS OF RNASE P PROTEINS AS ANTIBACTERIAL COMPOUNDS
ATE365036T1 (de) Creatinester-pronutrient-verbindungen und formulierungen
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
PT1140186E (pt) Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido fibrico para indicacoes cardiovasculares
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
BR0214529A (pt) compostos terapêuticos
BR9810481A (pt) Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas.
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina
BR9909697A (pt) Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas
BR9809439A (pt) Processos para preparação de benzotiofenos
BR9803829A (pt) Composto e processos para a preparação e para a purificação e o isolamento de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.